0 Items - $0.00
A to Z

Alternative structural projections:


8- Bromo- 2'- O- monobutyryladenosine- 3', 5'- cyclic monophosphorothioate, Rp- isomer ( Rp-8-Br-2'-O-MB-cAMPS ), sodium salt
Metabolically activatable form of the PKA inhibitor Rp-8-Br-cAMPS
Cat. No.: B 010
CAS No.: [788807-32-9]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: B 010-05
Unit: 5 µmol / ~2.6 mg
For other salt forms please inquire. Lipophilic precursor of the protein kinase A inhibitor Rp-8-Br-cAMPS (Cat. No. B 001). During metabolic activation by esterases the inhibitor and butyrate are released. Caution: Butyrate was shown to have distinct biological effects! Significantly more lipophilic and membrane-permeant compared to Rp-8-Br-cAMPS. Detailed technical information and updated reference list available for Rp-8-Br-cAMPS on request. Reference: Ruiz-Velasco et al., Circ. Res., 82, 557 - 565 (1998).
Cat. No. B 010
CAS number [788807-32-9]
Purity > 97% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Molecular formula C₁₄H₁₆BrN₅O₆PS · Na
Molecular weight [g/mol] 516.2
cAMP modified at the exocyclic oxygen equatorial (Rp-)
Modifications 8-cAMP, 2'-cAMP
Lipophilicity 2.53
Absorption max [nm] 264
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 17000
  • 1. Cobine C. A., Callaghan B. P.Keef K. D., Am. J. Physiol. Heart Circ. Physiol., 292, 3079 - 3088 (2007), "Role of L-type Calcium Channels and PKC in Active Tone Develpoment in Rabbit Coronary Artery"
  • 2. Johansson C., Aandahl E. M., Aukrust P., Müller F., Hansson V., Froeland S. S.Tasken K., 12th Protein Kinase Symp. NO/cGMP and Protein Kinase Signaling Bad Brückenau/Germany, 0, 0 - 0 (2000), "Protein Kinase A Type I Antagonist as an Immune-Modulating Therapy"
  • 3. Ruiz-Velasco V., Zhong J., Hume J. R.Keef K. D., Circ. Res., 82, 557 - 565 (1998), "Modulation of Ca2+ Channels by Cyclic Nucleotide Cross Activation of Opposing Protein Kinases in Rabbit Portal Vein"
  • 4. Tasken K., Aandahl E. M., Aukrust P., Müller F., Froland S. S.Hansson V., Intl. Patent Appl. PCT, 0, 0 - 0 (1998), "Use of Immunomodulating Agents"